Get the Stockscreener App
3.34
1.52%
0.05
After Hours:
3.35
0.01
+0.30%
Relay Therapeutics Inc stock is traded at $3.34, with a volume of 2.53M.
It is up +1.52% in the last 24 hours and down -19.71% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$3.29
Open:
$3.28
24h Volume:
2.53M
Relative Volume:
1.07
Market Cap:
$566.20M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-1.1929
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
-8.74%
1M Performance:
-19.71%
6M Performance:
-57.51%
1Y Performance:
-57.12%
1-Day Range:
$3.17
$3.35
1-Week Range:
$3.17
$3.91
52-Week Range:
$3.02
$10.72
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.34 | 566.20M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Head-To-Head Contrast: Relay Therapeutics (NASDAQ:RLAY) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition - Investing.com India
Arizona State Retirement System Acquires 7,547 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
HC Wainwright Reiterates “Buy” Rating for Relay Therapeutics (NASDAQ:RLAY) - Defense World
Rhumbline Advisers Acquires 13,532 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
New York State Common Retirement Fund Has $121,000 Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) - Yahoo Finance
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
The Goldman Sachs Group Lowers Relay Therapeutics (NASDAQ:RLAY) Price Target to $18.00 - Defense World
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year Low After Analyst Downgrade - Defense World
Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP - TipRanks
Relay Therapeutics stock target cut to $12 at Citizens JMP - Investing.com
Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial Developments - TipRanks
RLAY stock touches 52-week low at $3.34 amid market challenges - Investing.com
Relay Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relay Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Relay Therapeutics reports Q4 EPS (45c), consensus (55c) - TipRanks
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - The Manila Times
Relay Therapeutics, Inc. SEC 10-K Report - TradingView
What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnin - GuruFocus.com
What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings - Yahoo Finance
Relay Therapeutics to Participate in Two Upcoming Investor Conferences - WICZ
Can These Two Major Healthcare Conferences Reveal Relay Therapeutics' Next Big Move? - StockTitan
Relay Therapeutics (RLAY) to Release Earnings on Wednesday - MarketBeat
Savant Capital LLC Buys Shares of 29,088 Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics (RLAY) Projected to Post Quarterly Earnings on Thursday - Defense World
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 - The Manila Times
The Potential Rise in the Price of Relay Therapeutics Inc (RLAY) following insiders activity - Knox Daily
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Nasdaq
Relay Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
This Insider Has Just Sold Shares In Relay Therapeutics - Simply Wall St
Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap DownTime to Sell? - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 75,324 Shares - MarketBeat
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 140,182 Shares of Stock - MarketBeat
Relay Therapeutics: A Precision Oncology Play Worth The Risk - Seeking Alpha
Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock By Investing.com - Investing.com UK
Q2 Earnings Forecast for RLAY Issued By Leerink Partnrs - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down – Should You Sell? - Defense World
Q2 Earnings Estimate for RLAY Issued By Leerink Partnrs - Defense World
Quarterly Metrics: Quick and Current Ratios for Relay Therapeutics Inc (RLAY) - The Dwinnex
Brokers Issue Forecasts for RLAY Q1 Earnings - Defense World
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):